Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 375

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 4
Chunk 375
---
 Phase II registration-intent study in 3L GC with MET amplification.
In 2011, following the discovery and initial development of savolitinib by HUTCHMED, AstraZeneca and HUTCHMED entered a global licensing agreement to jointly develop and commercialize savolitinib. AstraZeneca is responsible for the commercialization of savolitinib in China and worldwide. The revenue we generate from savolitinib comprised of royalty revenue and manufacturing revenue of Orpathys, which we source from a third-party manufacturer and sell to AstraZeneca at cost. In 2024, savolitinib in-market sales were $45.1 million in 2024, down from $46.1 million in 2023, impacted by the launch and NRDL inclusion of competing same-class MET TKIs in China. Our consolidated revenue was $24.5 million, down 15% from last year of $28.9 million.
In 2021, 2022 and the first two months of 2023, Orpathys was sold as a self-pay drug. Following negotiations with the NHSA in January 2023, Orpathys were included in the updated NRDL at a 38% discount relative to the self-pay price, broadening patient access to this medicine. Following the contract renewal with the NHSA, the updated NRDL effective on January 1, 2025 will continue to include Orpathys at the same price as the 2023-24 NRDL price.
In March 2023, Orpathys was approved in the Macau Special Administrative Region. In February 2025, it was approved in Hong Kong Special Administrative Region under the “1+” mechanism.
Surufatinib (Sulanda in China)
Surufatinib was approved in China for non-pancreatic NETs in December 2020 and for pancreatic NETs in June 2021. It is being marketed by us in China under the brand name Sulanda. There are approximately 34,000 new patients per year in China. According to IQVIA tracking study report in the fourth quarter of 2023, Sulanda maintained its position in the market with 21% prescription share in NET treatment, ahead of competitors Sutent and Afinitor. Sulanda is also being investigated in a Phase II/III trial in a combination of surufatinib, camrelizumab (PD-1 antibody), nab-paclit